Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2018 16:00 ET | Source: TiGenix

Transparantiekennisgeving overeenkomstig Artikel 14 van de wet van 2 mei 2007

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} GEREGLEMENTEERDE INFORMATIEPERSBERICHT ...
December 20, 2017 01:00 ET | Source: TiGenix

TiGenix confirme l'orientation stratégique du Cx601 et de la plateforme de cellules souches dérivées de tissus adipeux (eASC)

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} COMMUNIQUÉ DE PRESSE TiGenix...
December 20, 2017 01:00 ET | Source: TiGenix

TiGenix bevestigt strategische focus op Cx601 en het uit vetweefsel afgeleide stamcelplatform (eASC)

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PERSBERICHT TiGenix bevestigt...
December 20, 2017 01:00 ET | Source: TiGenix

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE TiGenix confirms...
December 15, 2017 07:11 ET | Source: TiGenix

Takeda en TiGenix kondigen aan dat Cx601 (darvadstrocel) een positief CHMP-advies ontvangen heeft voor de behandeling van complexe perianale fistels bij de ziekte van Crohn

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PERSBERICHT GEREGLEMENTEERDE...
December 15, 2017 07:11 ET | Source: TiGenix

Takeda et TiGenix annoncent que le Cx601 (darvadstrocel) a reçu la décision favorable du CHMP dans le traitement des fistules périanales complexes de la maladie de Crohn

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} COMMUNIQUE DE PRESSE INFORMATION...
December 15, 2017 07:11 ET | Source: TiGenix

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn's disease

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE REGULATED INFORMATION...
December 14, 2017 18:20 ET | Source: TiGenix

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE REGULATED INFORMATION...
November 30, 2017 16:00 ET | Source: TiGenix

Transparantie Informatie

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PERSBERICHTGEREGLEMENTEERDE INFORMATIE ...
November 30, 2017 16:00 ET | Source: TiGenix

Transparency Information

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASEREGULATED INFORMATION ...